(Adnkronos) - In Italia, 24 milioni di persone convivono con malattie croniche, responsabili dell’85% dei decessi e di una spesa sanitaria di oltre 65 miliardi di euro all’anno. Patologie come scompenso cardiaco, diabete di tipo 2 e malattia renale cronica sono in aumento, complici l’invecchiamento della popolazione e i ritardi nella prevenzione e diagnosi.
Per affrontare questa sfida, The European House - Ambrosetti, con il supporto di AstraZeneca, ha realizzato un progetto innovativo: sei tavole rotonde regionali con oltre 40 esperti per ridisegnare la gestione della cronicità cardio-nefro-metabolica. I risultati, presentati durante l’evento “Ripensare le cronicità - L’impatto dell’innovazione per un SSN sostenibile che si è svolto a Roma, sottolineano il ruolo cruciale dell’innovazione farmaceutica per migliorare la vita dei pazienti e garantire la sostenibilità del Servizio Sanitario Nazionale.
Per affrontare questa sfida, The European House - Ambrosetti, con il supporto di AstraZeneca, ha realizzato un progetto innovativo: sei tavole rotonde regionali con oltre 40 esperti per ridisegnare la gestione della cronicità cardio-nefro-metabolica. I risultati, presentati durante l’evento “Ripensare le cronicità - L’impatto dell’innovazione per un SSN sostenibile che si è svolto a Roma, sottolineano il ruolo cruciale dell’innovazione farmaceutica per migliorare la vita dei pazienti e garantire la sostenibilità del Servizio Sanitario Nazionale.
Category
🗞
NewsTranscript
00:00In Italy, 24 million people live with chronic diseases, responsible for 85% of the deaths
00:13and a health expense of over 65 billion euros per year.
00:17Pathologies such as heart failure, type 2 diabetes and chronic kidney disease are increasing,
00:24as well as the aging of the population and the delays in the prevention of agnosis.
00:30To face this challenge, the European House Ambrosetti, with the support of AstraZeneca,
00:35has carried out an innovative project, six regional roundtables with more than 40 experts,
00:41to redesign the management of cardionephrometabolic chronicity.
00:46The results presented during the event, to rethink the chronicity of the impact of innovation
00:51for a sustainable national health system, which took place in Rome,
00:55underline the crucial role of pharmaceutical innovation to improve the lives of patients
01:01and guarantee the sustainability of the national health service.
01:05I focus on chronic kidney disease, a disease that is epidemic today.
01:10It is the main degenerative chronic disease, which has a number of patients
01:14from 2 to 7 times higher than other chronic diseases, such as diabetes, neoplasia,
01:22cardiopathy and chronic respiratory diseases.
01:26This disease has a huge negative impact on the patient's survival.
01:31Think that a 40-year-old patient in dialysis has the same life expectancy as a 80-year-old patient.
01:39This disease costs a lot, it costs 50,000 euros in the dialysis phase,
01:44so Italy spends 2.5 billion euros a year for 45,000 dialysis patients.
01:52Today we can treat it, we can put this disease in remission,
01:56through the glyphosate and other drugs that are already available.
02:01We can extend the life of these patients without dialysis for up to 20 years.
02:06The problem is that we have to be able to see and treat these patients,
02:11so the early recognition of this disease is essential,
02:14because it is an asymptomatic disease in the initial stages.
02:18Only 10% of patients know they have the disease and therefore turn to the nephrologist.
02:23A screening program is therefore very important.
02:26As the Italian Society of Nephrology, we have asked and obtained
02:31a law from the Vice-President of the Chamber, Mr. Moulet,
02:38on the screening and treatment of this disease in general medicine ambulatories.
02:43So, to create a network between general medicine and nephrology specialists.
02:49Only in this way will we be able to implement therapies with glyphosate
02:55and finally put this disease in remission.
02:59Pharmacies have a fundamental role in the treatment and prevention of this disease.
03:04Certainly, the role of the pharmacist is very important.
03:07The increase in chronicity, the ability of companies to provide new treatment tools,
03:13are two elements that must make us reflect on the tension we all have
03:18to maintain a healthy and balanced health service,
03:20therefore able to assist citizens as we are doing now.
03:25In this sense, the pharmacy of services,
03:27the pharmacists in the pharmacy of services,
03:29can contribute to help the doctor, also in light of the DM77,
03:33therefore this need to make a team in favor of the citizen,
03:37to be able to put into practice with the alterpessors,
03:42the electrocardiogram, the blood capillary sample,
03:46a series of first tests that can be useful to the doctor
03:50to frame the eventual development of a therapeutic approach for the patient.